Your Health, We Care
It is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) classified as New York Heart Association (NYHA) Class Ⅱ-Ⅲ, to improve their functional capacity and symptoms.
FDA，2025.04
It is indicated for the treatment of adult patients with symptomatic obstructive···【more】
Release date：2026-01-05Recommended：10
